文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

新型抗革兰阴性菌抗生素治疗期间耐药性的发生:地理流行病学与危险因素

Resistance development to new anti-Gram negatives antibiotics during treatment: geographical epidemiology and risk factors.
PubMed 文献 · Clin Microbiol Infect · 2026-02-08

本文综述了碳青霉烯耐药肠杆菌目细菌在接受新型抗生素治疗期间出现获得性耐药的流行病学、危险因素及临床影响。文献以病例报告和回顾性队列研究为主,头孢他啶-阿维巴坦耐药报道最多,机制以KPC Ω环突变(如KPC-31)最常见。预防策略包括优化PK/PD目标、治疗药物监测、及时感染源控制和抗菌药物管理。

要点

  • 头孢他啶-阿维巴坦治疗期间耐药报道最多,以KPC Ω环突变(如KPC-31)为主。
  • 美罗培南-韦博巴坦或亚胺培南-瑞来巴坦耐药少见,仅欧洲部分病例报告。
  • 预防需优化PK/PD、治疗药物监测、感染源控制及合理使用新型药物。

核心结论

  • 治疗中出现耐药是抗生素暴露的后果,但其影响可能被低估。

研究设计与样本

  • 检索PubMed/MEDLINE过去15年文献,包括临床报告、观察性研究和体外研究。

主要发现

  • 头孢他啶-阿维巴坦耐药机制以KPC Ω环突变(如KPC-31)最常见。
  • 美罗培南-韦博巴坦或亚胺培南-瑞来巴坦耐药不常见,仅欧洲部分病例报告。
  • 头孢地尔耐药主要由欧洲和美国报道,见于产NDM肠杆菌目细菌,常与铁转运缺陷、PBP3替换或blaNDM拷贝数增加相关。
  • 氨曲南-阿维巴坦耐药见于新加坡和美国部分产NDM大肠埃希菌,携带PBP3和CMY突变。

临床怎么用

  • 优化PK/PD目标、进行治疗药物监测、及时彻底感染源控制及抗菌药物管理以合理使用新型药物。

局限性

  • 文献稀疏,主要为病例报告或回顾性队列研究,多数未报告剂量、疗程或交叉耐药数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment-emergent resistance is increasingly reported in carbapenem-resistant Enterobacterales during therapy with newly developed antibiotics. However, standardized definitions and studies evaluating the impact of treatment-emergent resistance on patient outcome are lacking. OBJECTIVES: To review current evidence on the epidemiology, risk factors, and clinical impact of resistance emerging during or after exposure to novel antibiotics against carbapenem-resistant Enterobacterales and to explore strategies to mitigate this phenomenon. SOURCES: We searched PubMed/MEDLINE for studies published in the last 15 years, including clinical reports, observational studies, and in vitro studies focusing on ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, aztreonam-avibactam, eravacycline, and plazomicin. CONTENT: Literature on resistance development during treatment with novel antibiotics is sparse and mainly represented by case reports or retrospective cohort studies. In most cases, data including antibiotic dosages, duration, or cross-resistance to other antibiotics are not reported. Treatment-emergent resistance is best described for ceftazidime-avibactam, with Klebsiella pneumoniae carbapenemase (KPC) variants carrying Ω-loop mutations (e.g. KPC-31) as the most common reported mechanism worldwide. Resistance during or after meropenem-vaborbactam or imipenem-relebactam therapy is uncommon and only reported in selected cases from Europe where the drugs have been used more broadly. Cefiderocol resistance is mainly reported from Europe and United States in New-Delhi metallo-β-lactamase (NDM)-producing Enterobacterales and commonly linked to iron transporter defects, penicillin-binding protein 3 (PBP3) substitutions, or increased blaNDM copy number. For aztreonam-avibactam, resistance during or after treatment has been reported in selected strains of NDM-producing Escherichia coli isolates with PBP3 and CMY mutations from Singapore and United States. IMPLICATIONS: Treatment-emergent resistance is a consequence of antibiotic exposure, but its impact is likely underestimated. Preventive strategies include optimization of pharmacokinetic/pharmacodynamic targets, therapeutic drug monitoring, timely and complete source control, and stewardship-driven rational use of novel agents.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Falcone M, Tiseo G, Shields RK, et al. Resistance development to new anti-Gram negatives antibiotics during treatment: geographical epidemiology and risk factors. Clin Microbiol Infect. 2026. PMID: 41666984. doi:10.1016/j.cmi.2026.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。